ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 05/05/22

Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR Received a $25 million equity investment from Pfizer, with plans to jointly advance clinical development of ZN-c3, and ...

Gainers: Nutex Health (NUTX) +24%. Repligen (RGEN) +14%. Zentalis Pharmaceuticals (ZNTL) +14%. Alkermes (ALKS) +12%. Clever Leaves (CLVR) +8%. Losers: Molecular Partners (MOLN) -37%. Agile Therapeutics (AGRX) -28%. Immunome (IMNM) -1...

Nutex Health (NUTX) +14% on surging volume. Mattel (MAT) +12% on report it's held talks with buyout firms. Constellium (CSTM) +10% on Q1 results. Enphase Energy (ENPH) +9% on Q1 results. Comstock Mining (LODE) +7%. Zentalis Pharmaceuticals (ZNTL) +7%&#x...

Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Me...

Wall Street posted another day of losses on Monday, as technology retreated and volatility jumped. The Nasdaq led the decline, falling more than 2% on the session. Clinical trial data decided the fates of a couple of drug developers during the session. Veru (VERU) nearly tripled amid positive...

ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 demonstrated an ORR of 27.3% and a DCR of 90.9% in patients with uterine serous carcinoma (USC), ...

Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) dropped 30% on Friday after releasing initial phase 1b efficacy data on its candidate, ZN-c3, in combination with chemotherapy in heavily pretreated ovarian cancer patients. ZN-c3, a Wee1 inhibitor, demonstrated an objective response ...

ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 in combination with chemotherapy was well-tolerated, exhibiting a better hematologic and gastro...

Wells Fargo has initiated shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) with an overweight rating citing the company's lead asset ZN-c34 for uterine carcinoma and ovarian cancer. The firm has a $67 price target (36% upside based on Tuesday's close). Analyst Derek Archila said that data tha...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is collaborating with Caris Life Sciences to support clinical studies for its cancer drug programs. Under the partnership, Caris will sequence individuals’ exome and transcriptome, use real-world data to help inform clinical development and help i...